Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Patrick J Kerins. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Patrick J Kerins har rapporteret besiddelser eller handler i følgende virksomheder:
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Patrick J Kerins. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb APPN / Appian Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg APPN / Appian Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ARDX / Ardelyx, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-06-24 | ARDX | New Enterprise Associates 12, Limited Partnership | 510.442 | 14,0000 | 510.442 | 14,0000 | 7.146.188 | 162 | 32.89 | 9.642.249 | 134,93 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ARDX / Ardelyx, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AVTX / Avalo Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AVTX / Avalo Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BOX / Box, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BOX / Box, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BZFD / BuzzFeed, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BZFD / BuzzFeed, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CSBR / Champions Oncology, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CSBR / Champions Oncology, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-03-06 | CSBR | New Enterprise Associates 14, L.P. | 708.155 | 6,9900 | 708.155 | 6,9900 | 4.950.003 | 6 | 4.19 | -1.982.834 | -40,06 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb DERM / Journey Medical Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg DERM / Journey Medical Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GRPN / Groupon, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GRPN / Groupon, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GRTX / Galera Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-11-12 | GRTX | New Enterprise Associates 14, L.P. | 416.666 | 12,0000 | 416.666 | 12,0000 | 4.999.992 | 111 | 17.67 | 2.362.496 | 47,25 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GRTX / Galera Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2020-03-16 | IMRA | New Enterprise Associates 14, L.P. | 475.000 | 16,0000 | 118.750 | 64,0000 | 7.600.000 | 87 | 54.87 | -1.084.188 | -14,27 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb MRSN / Mersana Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-03-05 | MRSN | New Enterprise Associates 14, L.P. | 3.750.000 | 4,0000 | 150.000 | 100,0000 | 15.000.000 | 358 | 9.2800 | -13.608.000 | -90,72 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg MRSN / Mersana Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2019-08-28 | MRSN | New Enterprise Associates 14, L.P. | 1.211 | 2,9100 | 48 | 72,7500 | 3.524 | 40 | 1.4500 | -3.454 | -98,02 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SGMT / Sagimet Biosciences Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2023-07-18 | SGMT | NEW ENTERPRISE ASSOCIATES 13 LP | 30.000 | 16,0000 | 30.000 | 16,0000 | 480.000 | 188 | 18.4200 | 72.600 | 15,12 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SGMT / Sagimet Biosciences Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2023-07-18 | SGMT | NEW ENTERPRISE ASSOCIATES 13 LP | 662 | 16,0000 | 662 | 16,0000 | 10.592 | 118 | 2.2300 | -9.116 | -86,06 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SPT / Sprout Social, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SPT / Sprout Social, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SYBX / Synlogic, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SYBX / Synlogic, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TRVN / Trevena, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TRVN / Trevena, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb UTRS / Minerva Surgical, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg UTRS / Minerva Surgical, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Patrick J Kerins som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-14 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
S - Sale | -273.246 | 3.401.499 | -7,44 | 2,26 | -618.383 | 7.697.932 | |
2025-03-14 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
S - Sale | -61.448 | 3.674.745 | -1,64 | 2,01 | -123.769 | 7.401.671 | |
2025-03-14 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
S - Sale | -28.272 | 3.736.193 | -0,75 | 1,98 | -55.854 | 7.381.223 | |
2025-03-11 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
S - Sale | -13.629 | 3.764.465 | -0,36 | 1,95 | -26.620 | 7.352.753 | |
2025-03-11 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
S - Sale | -33.848 | 3.778.094 | -0,89 | 2,06 | -69.602 | 7.768.895 | |
2025-03-06 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
S - Sale | -11.127 | 3.811.942 | -0,29 | 2,10 | -23.372 | 8.006.984 | |
2025-03-06 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
S - Sale | -8.966 | 3.823.069 | -0,23 | 2,04 | -18.266 | 7.788.356 | |
2025-03-06 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
S - Sale | -1.438 | 3.832.035 | -0,04 | 2,07 | -2.978 | 7.936.144 | |
2024-05-15 |
|
4 | ZFOX |
ZeroFox Holdings, Inc.
Common Stock |
U - Other | -18.068.513 | 0 | -100,00 | ||||
2024-01-31 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Series A Common Stock |
J - Other | 13.139 | 13.139 | |||||
2024-01-31 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Series A Common Stock |
J - Other | -260.950 | 0 | -100,00 | ||||
2024-01-31 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Series A Common Stock |
J - Other | 260.950 | 260.950 | |||||
2024-01-31 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Series A Common Stock |
J - Other | -850.000 | 3.000.275 | -22,08 | ||||
2023-12-05 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
M - Exercise | 29.034 | 222.847 | 14,98 | ||||
2023-10-06 | 3 | SYBX |
SYNLOGIC, INC.
Common Stock |
2.922.773 | ||||||||
2023-09-05 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
M - Exercise | 29.033 | 193.813 | 17,62 | ||||
2023-07-20 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Series A Common Stock |
P - Purchase | 30.000 | 3.850.275 | 0,79 | 16,00 | 480.000 | 61.604.400 | |
2023-07-20 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Series A Common Stock |
S - Sale | -662 | 3.820.275 | -0,02 | 16,00 | -10.592 | 61.124.400 | |
2023-07-20 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Series A Common Stock |
X - Other | 13.404 | 3.820.937 | 0,35 | 0,79 | 10.653 | 3.036.881 | |
2023-07-20 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Series A Common Stock |
C - Conversion | 3.769.857 | 3.807.533 | 10.005,99 | ||||
2023-07-20 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Series A Common Stock |
J - Other | 37.676 | 37.676 | |||||
2023-07-20 |
|
4 | SGMT |
Sagimet Biosciences Inc.
Common Stock |
J - Other | -37.676 | 0 | -100,00 | ||||
2023-07-13 | 3 | SGMT |
Sagimet Biosciences Inc.
Common Stock |
37.676 | ||||||||
2023-06-06 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
M - Exercise | 29.033 | 164.780 | 21,39 | ||||
2023-04-06 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
M - Exercise | 29.033 | 135.747 | 27,21 | ||||
2023-02-10 |
|
4 | UTRS |
MINERVA SURGICAL INC
Common Stock |
P - Purchase | 24.437.927 | 34.437.052 | 244,40 | 0,20 | 5.000.000 | 7.045.821 | |
2023-01-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
U - Other | -5.925.287 | 0 | -100,00 | ||||
2022-12-06 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
M - Exercise | 26.679 | 106.714 | 33,33 | ||||
2022-10-26 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
S - Sale | -1.784.109 | 4.857.525 | -26,86 | 0,15 | -262.264 | 714.056 | |
2022-09-06 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
M - Exercise | 26.678 | 80.034 | 50,00 | ||||
2022-08-05 | 3 | ZFOX |
ZeroFox Holdings, Inc.
Common Stock |
18.068.513 | ||||||||
2022-06-07 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
M - Exercise | 26.678 | 53.356 | 100,00 | ||||
2022-04-07 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -255.463 | 2.611.050 | -8,91 | 1,10 | -281.827 | 2.880.510 | |
2022-04-07 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -439.088 | 2.866.513 | -13,28 | 1,07 | -469.429 | 3.064.589 | |
2022-03-07 |
|
4 | BZFD |
BuzzFeed, Inc.
Restricted Stock Units |
M - Exercise | -26.678 | 80.036 | -25,00 | ||||
2022-03-07 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
M - Exercise | 26.678 | 26.678 | |||||
2022-02-24 |
|
4 | BZFD |
BuzzFeed, Inc.
Restricted Stock Units |
A - Award | 106.714 | 106.714 | |||||
2022-01-26 |
|
4 | CSPR |
Casper Sleep Inc.
Common Stock |
U - Other | -6.222.502 | 0 | -100,00 | 6,90 | -42.935.264 | ||
2022-01-25 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -102.952 | 3.305.601 | -3,02 | 1,47 | -151.803 | 4.874.109 | |
2022-01-25 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -19.984 | 3.408.553 | -0,58 | 1,55 | -31.017 | 5.290.415 | |
2022-01-25 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -11.622 | 3.428.537 | -0,34 | 1,67 | -19.389 | 5.719.828 | |
2022-01-20 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -6.295 | 3.440.159 | -0,18 | 1,81 | -11.385 | 6.221.872 | |
2022-01-20 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -13.412 | 3.446.454 | -0,39 | 1,82 | -24.414 | 6.273.580 | |
2022-01-20 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -6.848 | 3.459.866 | -0,20 | 1,89 | -12.927 | 6.531.189 | |
2022-01-14 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -9.707 | 3.466.714 | -0,28 | 1,91 | -18.583 | 6.636.677 | |
2022-01-14 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -7.209 | 3.476.421 | -0,21 | 1,93 | -13.886 | 6.696.282 | |
2022-01-14 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -4.634 | 3.483.630 | -0,13 | 2,02 | -9.357 | 7.034.494 | |
2022-01-11 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -2.409 | 3.488.264 | -0,07 | 2,04 | -4.919 | 7.123.384 | |
2022-01-11 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -1.751 | 3.490.673 | -0,05 | 2,00 | -3.502 | 6.981.346 | |
2022-01-11 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -14.600 | 3.492.424 | -0,42 | 2,08 | -30.318 | 7.252.368 | |
2022-01-06 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -10.257 | 3.507.024 | -0,29 | 2,16 | -22.205 | 7.592.356 | |
2022-01-06 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -8.200 | 3.517.281 | -0,23 | 2,25 | -18.439 | 7.909.310 | |
2022-01-06 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -13.459 | 3.525.481 | -0,38 | 2,34 | -31.544 | 8.262.670 | |
2022-01-03 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -44.665 | 3.538.940 | -1,25 | 2,34 | -104.396 | 8.271.564 | |
2022-01-03 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -49.953 | 3.583.605 | -1,37 | 2,25 | -112.409 | 8.064.186 | |
2022-01-03 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -21.858 | 3.633.558 | -0,60 | 2,29 | -50.066 | 8.322.665 | |
2021-12-29 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -15.196 | 3.655.416 | -0,41 | 2,30 | -34.954 | 8.408.188 | |
2021-12-29 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -24.580 | 3.670.612 | -0,67 | 2,34 | -57.539 | 8.592.536 | |
2021-12-29 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -27.651 | 3.695.192 | -0,74 | 2,42 | -67.007 | 8.954.559 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -23.961 | 3.722.843 | -0,64 | 2,41 | -57.746 | 8.972.052 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -20.109 | 3.746.804 | -0,53 | 2,32 | -46.679 | 8.697.456 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -41.222 | 3.766.913 | -1,08 | 2,32 | -95.804 | 8.754.683 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -38.123 | 3.808.135 | -0,99 | 2,33 | -88.720 | 8.862.292 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -47.000 | 3.846.258 | -1,21 | 2,21 | -103.884 | 8.501.384 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -44.993 | 3.893.258 | -1,14 | 2,23 | -100.546 | 8.700.264 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -28.817 | 3.938.251 | -0,73 | 2,28 | -65.685 | 8.976.849 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -15.093 | 3.967.068 | -0,38 | 2,56 | -38.643 | 10.156.884 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -17.501 | 3.982.161 | -0,44 | 2,83 | -49.558 | 11.276.285 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -8.667 | 3.999.662 | -0,22 | 2,83 | -24.541 | 11.325.443 | |
2021-12-27 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
S - Sale | -5.666 | 4.008.329 | -0,14 | 2,95 | -16.693 | 11.809.339 | |
2021-12-07 |
|
4 | BZFD |
BuzzFeed, Inc.
Class A Common Stock |
A - Award | 15.333.892 | 15.333.892 | |||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series D Preferred Stock |
C - Conversion | -3.503.021 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series D Preferred Stock |
C - Conversion | 850.491 | 3.503.021 | 32,06 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series D Preferred Stock |
C - Conversion | 546.011 | 2.652.530 | 25,92 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series D Preferred Stock |
C - Conversion | 503.145 | 2.106.519 | 31,38 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series D Preferred Stock |
C - Conversion | 517.592 | 1.603.374 | 47,67 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series D Preferred Stock |
C - Conversion | 532.333 | 1.085.782 | 96,18 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series D Preferred Stock |
C - Conversion | 553.449 | 553.449 | |||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note |
C - Conversion | 0 | ||||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note |
C - Conversion | 0 | ||||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note |
C - Conversion | 0 | ||||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note |
C - Conversion | 0 | ||||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note |
C - Conversion | 0 | ||||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series D Preferred Stock |
C - Conversion | -3.409.709 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Subordinated Secured Convertible Promissory Note |
C - Conversion | 0 | ||||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series C Preferred Stock |
C - Conversion | -1.190.212 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Series B Preferred Stock |
C - Conversion | -596.183 | 0 | -100,00 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Common Stock |
P - Purchase | 1.300.000 | 9.999.125 | 14,94 | 12,00 | 15.600.000 | 119.989.500 | |
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Common Stock |
C - Conversion | 3.503.021 | 8.699.125 | 67,42 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Common Stock |
C - Conversion | 3.409.709 | 5.196.104 | 190,87 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Common Stock |
C - Conversion | 1.190.212 | 1.786.395 | 199,64 | ||||
2021-10-28 |
|
4 | UTRS |
MINERVA SURGICAL INC
Common Stock |
C - Conversion | 596.183 | 596.183 | |||||
2021-05-21 |
|
4 | COUR |
Coursera, Inc.
Common Stock |
J - Other | 70.394 | 70.394 | |||||
2021-05-21 |
|
4 | COUR |
Coursera, Inc.
Common Stock |
J - Other | -1.398.025 | 0 | -100,00 | ||||
2021-05-21 |
|
4 | COUR |
Coursera, Inc.
Common Stock |
J - Other | 1.398.025 | 1.398.025 | |||||
2021-05-21 |
|
4 | COUR |
Coursera, Inc.
Common Stock |
J - Other | -4.553.828 | 13.661.886 | -25,00 | ||||
2021-04-05 |
|
4 | COUR |
Coursera, Inc.
Series F Preferred Stock |
C - Conversion | -1.470.588 | 0 | -100,00 | ||||
2021-04-05 |
|
4 | COUR |
Coursera, Inc.
Series E Preferred Stock |
C - Conversion | -833.333 | 0 | -100,00 | ||||
2021-04-05 |
|
4 | COUR |
Coursera, Inc.
Series D Preferred Stock |
C - Conversion | -66.667 | 0 | -100,00 | ||||
2021-04-05 |
|
4 | COUR |
Coursera, Inc.
Series C Preferred Stock |
C - Conversion | -4.908.216 | 0 | -100,00 | ||||
2021-04-05 |
|
4 | COUR |
Coursera, Inc.
Series B Preferred Stock |
C - Conversion | -1.019.805 | 0 | -100,00 | ||||
2021-04-05 |
|
4 | COUR |
Coursera, Inc.
Series A Preferred Stock |
C - Conversion | -9.590.105 | 0 | -100,00 | ||||
2021-04-05 |
|
4 | COUR |
Coursera, Inc.
Common Stock |
C - Conversion | 17.888.714 | 18.215.714 | 5.470,55 | ||||
2021-03-30 | 3 | COUR |
Coursera, Inc.
Common Stock |
327.000 | ||||||||
2020-11-17 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | 38.644 | 38.644 | |||||
2020-11-17 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | -767.500 | 0 | -100,00 | ||||
2020-11-17 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | 767.500 | 767.500 | |||||
2020-11-17 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
J - Other | -2.500.000 | 3.082.854 | -44,78 | ||||
2020-11-13 |
|
4 | NET |
Cloudflare, Inc.
Class B Common Stock |
C - Conversion | -13.161.963 | 10.398.379 | -55,86 | ||||
2020-11-13 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | 203.454 | 203.454 | |||||
2020-11-13 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | -4.040.723 | 0 | -100,00 | ||||
2020-11-13 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | 4.040.723 | 4.040.723 | |||||
2020-11-13 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | -13.161.963 | 2.763.583 | -82,65 | ||||
2020-11-13 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
C - Conversion | 13.161.963 | 15.925.546 | 476,26 | ||||
2020-09-16 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | 372 | 3.594 | 11,55 | ||||
2020-09-16 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | 830 | 3.222 | 34,70 | ||||
2020-09-16 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2020-09-16 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2020-09-16 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | -20.000 | 0 | -100,00 | ||||
2020-09-16 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | 20.000 | 20.000 | |||||
2020-09-16 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | -2.000.000 | 5.959.520 | -25,13 | ||||
2020-08-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
S - Sale | -448.936 | 5.582.854 | -7,44 | 27,50 | -12.345.740 | 153.528.485 | |
2020-08-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
S - Sale | -2.992.910 | 6.031.790 | -33,16 | 27,50 | -82.305.025 | 165.874.225 | |
2020-08-18 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
S - Sale | -120.904 | 0 | -100,00 | 40,03 | -4.840.005 | ||
2020-08-18 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
S - Sale | -112.435 | 120.904 | -48,19 | 39,50 | -4.441.643 | 4.776.204 | |
2020-08-18 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
S - Sale | -12.565 | 233.339 | -5,11 | 38,68 | -486.069 | 9.026.579 | |
2020-08-13 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
S - Sale | -14.096 | 245.904 | -5,42 | 40,00 | -563.908 | 9.837.340 | |
2020-08-13 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
S - Sale | -50.508 | 260.000 | -16,27 | 37,79 | -1.908.753 | 9.825.686 | |
2020-08-10 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
S - Sale | -1.100 | 310.508 | -0,35 | 38,91 | -42.806 | 12.083.264 | |
2020-08-10 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
S - Sale | -13.909 | 311.608 | -4,27 | 37,77 | -525.354 | 11.769.683 | |
2020-08-10 |
|
4 | NET |
Cloudflare, Inc.
Class B Common Stock |
C - Conversion | -19.763.347 | 23.560.342 | -45,62 | ||||
2020-08-10 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | 325.517 | 325.517 | |||||
2020-08-10 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | -6.465.156 | 0 | -100,00 | ||||
2020-08-10 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | 6.465.156 | 6.465.156 | |||||
2020-08-10 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | -21.059.140 | 2.763.583 | -88,40 | ||||
2020-08-10 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
C - Conversion | 19.763.347 | 23.822.723 | 486,86 | ||||
2020-06-12 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 137 | 11.324 | 1,22 | ||||
2020-06-12 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 121 | 11.187 | 1,09 | ||||
2020-06-12 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 10.825 | 11.066 | 4.491,70 | ||||
2020-06-12 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -455.222 | 0 | -100,00 | ||||
2020-06-12 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 455.222 | 455.222 | |||||
2020-06-12 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -1.482.809 | 8.086.401 | -15,50 | ||||
2020-05-22 |
|
4 | SURF |
Surface Oncology, Inc.
Common Stock |
S - Sale | -420.000 | 2.892.877 | -12,68 | 3,66 | -1.535.562 | 10.576.648 | |
2020-05-21 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
S - Sale | -81.376 | 0 | -100,00 | 27,55 | -2.241.901 | ||
2020-05-21 |
|
4 | NET |
Cloudflare, Inc.
Class B Common Stock |
C - Conversion | -5.264.785 | 43.323.689 | -10,84 | ||||
2020-05-21 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | 81.376 | 81.376 | |||||
2020-05-21 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | -1.616.289 | 0 | -100,00 | ||||
2020-05-21 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | 1.616.289 | 1.616.289 | |||||
2020-05-21 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
J - Other | -5.264.785 | 4.059.376 | -56,46 | ||||
2020-05-21 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
C - Conversion | 5.264.785 | 9.324.161 | 129,69 | ||||
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Stock Purchase Warrant (right to buy) |
X - Other | -70.593 | 0 | -100,00 | ||||
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
S - Sale | -1.211 | 11.959.520 | -0,01 | 2,91 | -3.524 | 34.802.203 | |
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
X - Other | 70.593 | 11.960.731 | 0,59 | 0,05 | 3.530 | 598.037 | |
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | 745 | 2.392 | 45,23 | ||||
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | 1.647 | 1.647 | |||||
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | -20.000 | 0 | -100,00 | ||||
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | 20.000 | 20.000 | |||||
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | -40.000 | 0 | -100,00 | ||||
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | 40.000 | 40.000 | |||||
2020-04-13 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
J - Other | -4.000.000 | 7.959.520 | -33,45 | ||||
2020-04-03 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
D - Sale to Issuer | -6.135.234 | 0 | -100,00 | ||||
2020-03-16 |
|
4 | IMRA |
IMARA Inc.
Series B Preferred Stock |
C - Conversion | -5.625.926 | 0 | -100,00 | ||||
2020-03-16 |
|
4 | IMRA |
IMARA Inc.
Series A Preferred Stock |
C - Conversion | -15.323.454 | 0 | -100,00 | ||||
2020-03-16 |
|
4 | IMRA |
IMARA Inc.
Series Seed Preferred Stock |
C - Conversion | -1.342.780 | 0 | -100,00 | ||||
2020-03-16 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
P - Purchase | 475.000 | 4.013.995 | 13,42 | 16,00 | 7.600.000 | 64.223.920 | |
2020-03-16 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
C - Conversion | 3.538.995 | 3.538.995 | |||||
2020-03-10 |
|
4 | CSBR |
CHAMPIONS ONCOLOGY, INC.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -859.375 | 0 | -100,00 | ||||
2020-03-10 |
|
4 | CSBR |
CHAMPIONS ONCOLOGY, INC.
Common Stock |
S - Sale | -708.155 | 1.713.720 | -29,24 | 6,99 | -4.950.003 | 11.978.903 | |
2020-03-10 |
|
4 | CSBR |
CHAMPIONS ONCOLOGY, INC.
Common Stock |
X - Other | 859.375 | 2.421.875 | 55,00 | 5,76 | 4.950.000 | 13.950.000 | |
2020-02-12 |
|
4 | CSPR |
Casper Sleep Inc.
Common Stock |
P - Purchase | 1.250.000 | 6.222.412 | 25,14 | 12,00 | 15.000.000 | 74.668.944 | |
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2020-02-06 | 3 | CSPR |
Casper Sleep Inc.
Common Stock |
9.944.824 | ||||||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -268.679 | 0 | -100,00 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -832.126 | 0 | -100,00 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -1.837.275 | 0 | -100,00 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -6.086.620 | 0 | -100,00 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
C - Conversion | 268.679 | 9.024.700 | 3,07 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
C - Conversion | 832.126 | 8.756.021 | 10,50 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
C - Conversion | 1.837.275 | 7.923.895 | 30,19 | ||||
2019-12-18 |
|
4 | SPT |
Sprout Social, Inc.
Class A Common Stock |
C - Conversion | 6.086.620 | 6.086.620 | |||||
2019-12-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
A - Award | 400.000 | 9.569.210 | 4,36 | 6,25 | 2.500.000 | 59.807.562 | |
2019-11-29 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -1.166.755 | 4.270.691 | -21,46 | 2,52 | -2.941.739 | 10.767.693 | |
2019-11-29 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
S - Sale | -117.164 | 5.437.446 | -2,11 | 2,45 | -287.134 | 13.325.549 | |
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.354.829 | 0 | -100,00 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -9.600.000 | 0 | -100,00 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -8.975.000 | 0 | -100,00 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Common Stock |
P - Purchase | 416.666 | 4.358.047 | 10,57 | 12,00 | 4.999.992 | 52.296.564 | |
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Common Stock |
C - Conversion | 267.935 | 3.941.381 | 7,29 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Common Stock |
C - Conversion | 1.898.524 | 3.673.446 | 106,96 | ||||
2019-11-12 |
|
4 | GRTX |
Galera Therapeutics, Inc.
Common Stock |
C - Conversion | 1.774.922 | 1.774.922 | |||||
2019-11-05 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
11.850.574 | ||||||||
2019-11-05 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
11.850.574 | ||||||||
2019-11-05 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
11.850.574 | ||||||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Class B Common Stock |
C - Conversion | 42.463.920 | 48.588.474 | 693,34 | ||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -4.059.376 | 0 | -100,00 | ||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -7.183.310 | 0 | -100,00 | ||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -35.280.610 | 0 | -100,00 | ||||
2019-09-18 |
|
4 | NET |
Cloudflare, Inc.
Class A Common Stock |
C - Conversion | 4.059.376 | 4.059.376 | |||||
2019-03-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
P - Purchase | 3.750.000 | 11.890.138 | 46,07 | 4,00 | 15.000.000 | 47.560.552 | |
2019-01-22 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
U - Other | -1.333 | 0 | -100,00 | 75,00 | -99.975 | ||
2019-01-22 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
U - Other | -9.681.038 | 0 | -100,00 | 75,00 | -726.077.850 | ||
2018-12-14 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 645.161 | 6.135.234 | 11,75 | 15,50 | 9.999.996 | 95.096.127 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock |
C - Conversion | -1.124.301 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -437.706 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
S - Sale | -4.349 | 437.706 | -0,98 | 5,00 | -21.745 | 2.188.530 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
X - Other | 181.190 | 442.055 | 69,46 | 0,12 | 21.743 | 53.047 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock |
X - Other | -181.190 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -3.279.627 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
S - Sale | -1.177 | 3.279.627 | -0,04 | 5,00 | -5.885 | 16.398.135 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
X - Other | 49.030 | 3.280.804 | 1,52 | 0,12 | 5.884 | 393.696 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock |
X - Other | -49.030 | 0 | -100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 1.800.000 | 6.641.634 | 37,18 | 5,00 | 9.000.000 | 33.208.170 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 4.841.634 | 4.841.634 | |||||
2018-09-10 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 3.000.000 | 82.978.668 | 3,75 | 1,67 | 5.000.100 | 138.300.546 | |
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Warrant to purchase Common Stock |
J - Other | 40.702 | 40.702 | |||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Warrant to purchase Series D Preferred Stock |
J - Other | -684.911 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Series D Preferred Stock |
C - Conversion | -16.502.833 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Series C Preferred Stock |
C - Conversion | -3.337.206 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Series B Preferred Stock |
C - Conversion | -3.645.307 | 0 | -100,00 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
P - Purchase | 545.455 | 2.484.870 | 28,12 | 11,00 | 6.000.005 | 27.333.570 | |
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
C - Conversion | 980.715 | 1.939.415 | 102,30 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
C - Conversion | 432.033 | 958.700 | 82,03 | ||||
2018-08-01 |
|
4 | LQDA |
Liquidia Technologies Inc
Common Stock |
C - Conversion | 515.547 | 526.667 | 4.636,21 | ||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-07-25 | 3 | LQDA |
Liquidia Technologies Inc
Common Stock |
22.240 | ||||||||
2018-05-30 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
A - Award | 416.667 | 9.169.210 | 4,76 | 4,00 | 1.666.668 | 36.676.840 | |
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
C - Conversion | -12.679.970 | 0 | -100,00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
U - Other | -12.679.970 | 0 | -100,00 | ||||
2018-05-09 |
|
4 | MULE |
MULESOFT, INC
Class A Common Stock |
C - Conversion | 12.679.970 | 12.679.970 | |||||
2018-04-23 |
|
4 | SURF |
Surface Oncology, Inc.
Series A Preferred Stock |
C - Conversion | -6.995.000 | 0 | -100,00 | ||||
2018-04-23 |
|
4 | SURF |
Surface Oncology, Inc.
Common Stock |
P - Purchase | 133.333 | 3.312.877 | 4,19 | 15,00 | 1.999.995 | 49.693.155 | |
2018-04-23 |
|
4 | SURF |
Surface Oncology, Inc.
Common Stock |
C - Conversion | 3.179.544 | 3.179.544 | |||||
2018-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 6.000.000 | 79.978.672 | 8,11 | 1,92 | 11.500.200 | 153.295.121 | |
2018-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 571.164 | 73.978.672 | 0,78 | 1,90 | 1.087.553 | 140.862.789 | |
2018-03-27 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Warrant to Purchase Common Stock |
P - Purchase | 707.964 | 707.964 | 0,12 | 88.496 | 88.496 | ||
2018-03-27 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 707.964 | 3.466.003 | 25,67 | 2,70 | 1.911.503 | 9.358.208 | |
2018-03-23 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 294.090 | 73.407.508 | 0,40 | 1,95 | 572.358 | 142.865.692 | |
2018-03-23 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 869.574 | 73.113.418 | 1,20 | 1,90 | 1.655.669 | 139.207.948 | |
2018-03-23 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 104.844 | 72.243.844 | 0,15 | 1,81 | 189.820 | 130.797.480 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 12.634 | 9.681.129 | 0,13 | 59,82 | 755.708 | 579.080.604 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 17.248 | 9.668.495 | 0,18 | 59,76 | 1.030.813 | 577.829.869 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 1.600 | 9.651.247 | 0,02 | 59,15 | 94.634 | 570.832.655 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 30.321 | 9.649.647 | 0,32 | 58,28 | 1.767.153 | 562.395.902 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 17.859 | 9.619.326 | 0,19 | 57,34 | 1.024.114 | 551.614.478 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 4.080 | 9.601.467 | 0,04 | 56,66 | 231.174 | 544.022.961 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 6.399 | 9.597.387 | 0,07 | 55,01 | 352.005 | 527.946.500 | |
2018-03-06 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 26.304 | 9.590.988 | 0,28 | 54,32 | 1.428.875 | 520.997.814 | |
2018-03-02 |
|
4 | TNTR |
Tintri, Inc.
Note Purchase Agreement (obligation to purchase) |
E - Other | 0 | ||||||
2018-02-21 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2.000.000 | 5.490.073 | 57,31 | 6,00 | 12.000.000 | 32.940.438 | |
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | -2.724.202 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 509 | 1.523 | 50,20 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 1.014 | 1.014 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | -13.621 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 13.621 | 13.621 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | -27.242 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | 27.242 | 27.242 | |||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
J - Other | -2.724.202 | 0 | -100,00 | ||||
2018-02-15 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
C - Conversion | 2.724.202 | 2.724.202 | |||||
2018-01-26 |
|
4 | SYBX |
SYNLOGIC, INC.
Common Stock |
A - Award | 410.000 | 4.228.940 | 10,74 | 9,75 | 3.997.500 | 41.232.165 | |
2018-01-09 | 3 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value |
8.282.616 | ||||||||
2018-01-09 | 3 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value |
8.282.616 | ||||||||
2017-12-19 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 2.000.000 | 5.554.610 | 56,26 | 5,00 | 10.000.000 | 27.773.050 | |
2017-11-27 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | -569.620 | 2.724.202 | -17,29 | ||||
2017-11-27 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
S - Sale | -569.620 | 0 | -100,00 | 19,49 | -11.101.894 | ||
2017-11-27 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
C - Conversion | 569.620 | 569.620 | |||||
2017-11-21 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | -2.820.516 | 3.293.822 | -46,13 | ||||
2017-11-21 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
S - Sale | -2.820.516 | 0 | -100,00 | 19,49 | -54.971.857 | ||
2017-11-21 |
|
4 | APPN |
APPIAN CORP
Class A Common Stock |
C - Conversion | 2.820.516 | 2.820.516 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | 504 | 504 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2017-11-08 |
|
4 | CRCM |
Care.com Inc
Common Stock |
J - Other | -1.000.000 | 2.256.013 | -30,71 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A-1 Junior Preferred Stock |
C - Conversion | -2.927.708 | 0 | -100,00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stoc |
C - Conversion | -1.402.870 | 0 | -100,00 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 550.000 | 4.909.956 | 12,61 | 17,00 | 9.350.000 | 83.469.252 | |
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 2.927.708 | 4.359.956 | 204,41 | ||||
2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 1.402.870 | 1.432.248 | 4.775,24 | ||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
2017-08-30 |
|
4 | SYBX |
SYNLOGIC, INC.
Common Stock |
A - Award | 3.394.439 | 3.818.940 | 799,63 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series C-1 Preferred Stock |
C - Conversion | -2.216.626 | 0 | -100,00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series B-1 Preferred Stock |
C - Conversion | -18.001.419 | 0 | -100,00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Series A-1 Preferred Stock |
C - Conversion | -11.931.173 | 0 | -100,00 | ||||
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
P - Purchase | 1.000.000 | 8.140.138 | 14,01 | 15,00 | 15.000.000 | 122.102.070 | |
2017-07-06 |
|
4 | MRSN |
Mersana Therapeutics, Inc.
Common Stock |
C - Conversion | 7.140.138 | 7.140.138 | |||||
2017-05-31 |
|
4 | APPN |
APPIAN CORP
Class B Common Stock |
C - Conversion | 6.114.338 | 6.114.338 | |||||
2017-05-31 |
|
4 | APPN |
APPIAN CORP
Series B Convertible Preferred Stock |
C - Conversion | -6.114.338 | 0 | -100,00 | ||||
2017-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
P - Purchase | 12.870.000 | 72.139.000 | 21,71 | 0,70 | 9.009.000 | 50.497.300 | |
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Class B Common Stock |
J - Other | 12.679.970 | 12.679.970 | |||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series G Preferred Stock |
C - Conversion | -605.668 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series F Preferred Stock |
C - Conversion | -2.064.048 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series E Preferred Stock |
C - Conversion | -8.000.038 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Series A Preferred Stock |
C - Conversion | -1.689.436 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
J - Other | -12.679.970 | 0 | -100,00 | ||||
2017-03-22 |
|
4 | MULE |
MULESOFT, INC
Common Stock |
C - Conversion | 12.359.190 | 12.679.970 | 3.852,86 | ||||
2017-03-16 | 3 | MULE |
MULESOFT, INC
Common Stock |
641.560 | ||||||||
2017-03-16 | 3 | MULE |
MULESOFT, INC
Common Stock |
641.560 | ||||||||
2017-02-14 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -1.099.996 | 952.809 | -53,59 | 2,01 | -2.211.432 | 1.915.527 | |
2016-11-29 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 869.565 | 2.758.039 | 46,05 | 5,75 | 4.999.999 | 15.858.724 | |
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Series B-2 Preferred Stock |
C - Conversion | -4.362.472 | 0 | -100,00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Series B-1 Preferred Stock |
C - Conversion | -4.689.657 | 0 | -100,00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -12.447.605 | 0 | -100,00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Warrants to Purchase Common Stock |
X - Other | -80.658 | 0 | -100,00 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 338.462 | 3.490.073 | 10,74 | 13,00 | 4.400.006 | 45.370.949 | |
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 623.210 | 3.151.611 | 24,65 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 669.951 | 2.528.401 | 36,05 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.778.227 | 1.858.450 | 2.216,60 | ||||
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
S - Sale | -435 | 80.223 | -0,54 | 13,00 | -5.655 | 1.042.899 | |
2016-10-31 |
|
4 | RARX |
Ra Pharmaceuticals, Inc.
Common Stock |
X - Other | 80.658 | 80.658 | 0,07 | 5.646 | 5.646 | ||
2016-09-30 |
|
4/A | ROKA |
Roka BioScience, Inc.
Series A Convertible Preferred Stock |
P - Purchase | 4.000 | 4.000 | |||||
2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Warrant to Purchase Common Stock (right to buy) |
P - Purchase | 5.714.286 | 5.714.286 | |||||
2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Series A Convertible Preferred Stock |
P - Purchase | 4.000 | 4.000 | |||||
2016-09-20 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -7.471 | 2.052.805 | -0,36 | 0,75 | -5.603 | 1.539.604 | |
2016-09-15 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -10.000 | 2.060.276 | -0,48 | 0,74 | -7.400 | 1.524.604 | |
2016-09-15 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 461.538 | 3.554.610 | 14,92 | 13,00 | 5.999.994 | 46.209.930 | |
2016-08-31 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -50.000 | 2.070.276 | -2,36 | 1,01 | -50.440 | 2.088.494 | |
2016-08-26 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -1.200 | 2.120.276 | -0,06 | 1,21 | -1.452 | 2.565.534 | |
2016-08-02 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy) |
P - Purchase | 20.120.724 | 20.120.724 | |||||
2016-08-02 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock |
P - Purchase | 20.120.724 | 55.418.811 | 57,00 | 0,10 | 2.000.000 | 5.508.630 | |
2016-07-21 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -8.989 | 2.121.476 | -0,42 | 1,33 | -11.957 | 2.821.987 | |
2016-07-21 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -14.158 | 2.130.465 | -0,66 | 1,24 | -17.550 | 2.640.924 | |
2016-07-21 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -534 | 2.144.623 | -0,02 | 1,17 | -625 | 2.509.209 | |
2016-07-20 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 763.650 | 8.752.543 | 9,56 | 8,73 | 6.666.664 | 76.409.700 | |
2016-07-15 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
S - Sale | -13.382 | 2.145.157 | -0,62 | 1,20 | -16.060 | 2.574.403 | |
2016-06-14 |
|
4 | OPWR |
OPOWER, INC.
Common Stock |
U - Other | -8.989.766 | 0 | -100,00 | 10,30 | -92.594.590 | ||
2016-03-18 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 710.429 | 9.564.684 | 8,02 | 35,19 | 24.999.997 | 336.581.230 | |
2016-03-01 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
A - Award | 13.761 | 35.853 | 62,29 | ||||
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Series B Convertible Redeemable Preferred Stock |
C - Conversion | -4.423.723 | 0 | -100,00 | ||||
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Series A Convertible Redeemable Preferred Stock |
C - Conversion | -13.848.000 | 0 | -100,00 | ||||
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
P - Purchase | 900.324 | 3.093.072 | 41,06 | 8,00 | 7.202.592 | 24.744.576 | |
2016-02-17 |
|
4 | PTI |
PROTEOSTASIS THERAPEUTICS, INC.
Common Stock |
C - Conversion | 2.192.748 | 2.192.748 | |||||
2016-02-04 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
D - Sale to Issuer | -3.943.269 | 0 | -100,00 | ||||
2016-01-14 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 500.000 | 7.988.893 | 6,68 | 10,00 | 5.000.000 | 79.888.930 | |
2016-01-12 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 1.111.111 | 5.854.351 | 23,43 | 9,00 | 9.999.999 | 52.689.159 | |
2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
118.538.000 | ||||||||
2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share |
118.538.000 | ||||||||
2015-12-15 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -37.028 | 0 | -100,00 | 13,32 | -493.306 | ||
2015-12-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -37.540 | 37.028 | -50,34 | 13,25 | -497.458 | 490.673 | |
2015-12-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -35.146 | 74.568 | -32,03 | 13,53 | -475.536 | 1.008.927 | |
2015-12-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -47.590 | 109.714 | -30,25 | 13,41 | -638.363 | 1.471.682 | |
2015-12-08 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -55.100 | 157.304 | -25,94 | 13,26 | -730.461 | 2.085.379 | |
2015-12-08 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -23.591 | 212.404 | -10,00 | 13,10 | -308.948 | 2.781.643 | |
2015-12-08 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -28.786 | 235.995 | -10,87 | 13,08 | -376.613 | 3.087.570 | |
2015-12-03 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -19.698 | 264.781 | -6,92 | 13,14 | -258.745 | 3.478.057 | |
2015-12-03 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -33.101 | 284.479 | -10,42 | 13,25 | -438.482 | 3.768.436 | |
2015-12-03 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -30.327 | 317.580 | -8,72 | 13,11 | -397.450 | 4.162.045 | |
2015-11-30 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -32.135 | 347.907 | -8,46 | 13,17 | -423.314 | 4.582.979 | |
2015-11-30 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -18.636 | 380.042 | -4,67 | 13,24 | -246.785 | 5.032.668 | |
2015-11-30 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -25.148 | 398.678 | -5,93 | 13,22 | -332.469 | 5.270.722 | |
2015-11-24 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -16.816 | 423.826 | -3,82 | 13,23 | -222.405 | 5.605.438 | |
2015-11-24 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -32.202 | 440.642 | -6,81 | 13,59 | -437.677 | 5.989.030 | |
2015-11-24 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -49.387 | 472.844 | -9,46 | 13,39 | -661.149 | 6.330.010 | |
2015-11-20 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -12.623 | 522.231 | -2,36 | 13,46 | -169.945 | 7.030.848 | |
2015-11-20 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -21.838 | 534.854 | -3,92 | 13,63 | -297.720 | 7.291.718 | |
2015-10-23 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
U - Other | -8.196.614 | 0 | -100,00 | 1,75 | -14.344.074 | ||
2015-10-23 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
U - Other | -75.229 | 15.625 | -82,80 | 1,75 | -131.651 | 27.344 | |
2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Series B Convertible Preferred Stock |
C - Conversion | -16.638.880 | 0 | -100,00 | ||||
2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Common Stock |
C - Conversion | 594.245 | 594.245 | |||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
P - Purchase | 857.142 | 2.971.517 | 40,54 | 7,00 | 5.999.994 | 20.800.619 | |
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
J - Other | 31.650 | 2.114.375 | 1,52 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
J - Other | 257.516 | 1.499.166 | 20,74 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Series D Preferred Stock |
C - Conversion | -583.559 | 0 | -100,00 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.241.650 | 0 | -100,00 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
C - Conversion | 583.559 | 2.082.725 | 38,93 | ||||
2015-10-06 |
|
4 | MIRN |
Mirna Therapeutics, Inc.
Common Stock |
C - Conversion | 1.241.650 | 1.241.650 | |||||
2015-07-01 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
A - Award | 12.987 | 22.092 | 142,64 | ||||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock Warrant (right to buy) |
P - Purchase | 560.748 | 560.748 | 0,12 | 70.094 | 70.094 | ||
2015-06-09 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 1.869.159 | 7.488.893 | 33,26 | 10,70 | 20.000.001 | 80.131.155 | |
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 504 | 1.333 | 60,80 | ||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2015-06-02 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -1.000.000 | 8.854.255 | -10,15 | ||||
2015-05-11 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
U - Other | -120 | 0 | -100,00 | 46,00 | -5.520 | ||
2015-05-11 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
U - Other | -2.384.221 | 0 | -100,00 | 46,00 | -109.674.166 | ||
2015-03-24 | 3 | CSBR |
CHAMPIONS ONCOLOGY, INC.
Common Stock |
37.500.000 | ||||||||
2015-03-24 | 3 | CSBR |
CHAMPIONS ONCOLOGY, INC.
Common Stock |
37.500.000 | ||||||||
2015-02-05 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Series B Redeemable Convertible Preferred Stock |
C - Conversion | -5.373.396 | 0 | -100,00 | ||||
2015-02-05 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 500.000 | 1.888.474 | 36,01 | 10,00 | 5.000.000 | 18.884.740 | |
2015-02-05 |
|
4 | TCON |
Tracon Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.388.474 | 1.388.474 | |||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
8% Convertible Note Issued 9/9/2013 |
C - Conversion | |||||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
8% Convertible Note Issued 12/2/2014 |
C - Conversion | |||||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
8% Convertible Note Issued 2/26/14 |
C - Conversion | |||||||
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
P - Purchase | 23.457 | 2.158.539 | 1,10 | 11,00 | 258.027 | 23.743.929 | |
2015-02-02 |
|
4 | ZSAN |
Zosano Pharma Corp
Common Stock |
C - Conversion | 341.201 | 2.135.082 | 19,02 | 9,35 | 3.190.229 | 19.963.017 | |
2015-01-29 |
|
4 | BOX |
BOX INC
Class B Common Stock |
J - Other | 2.091.457 | 2.091.457 | |||||
2015-01-29 |
|
4 | BOX |
BOX INC
Series E Preferred Stock |
C - Conversion | -274.916 | 0 | -100,00 | ||||
2015-01-29 |
|
4 | BOX |
BOX INC
Series D2 Preferred Stock |
C - Conversion | -1.653.761 | 0 | -100,00 | ||||
2015-01-29 |
|
4 | BOX |
BOX INC
Existing Class A Common Stock |
J - Other | -2.091.457 | 0 | -100,00 | ||||
2015-01-29 |
|
4 | BOX |
BOX INC
Existing Class A Common Stock |
C - Conversion | 1.928.677 | 2.091.457 | 1.184,84 | ||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-26 | 3 | ZSAN |
Zosano Pharma Corp
Common Stock |
3.587.762 | ||||||||
2015-01-22 | 3 | BOX |
BOX INC
Existing Class A Common Stock |
325.560 | ||||||||
2015-01-22 | 3 | BOX |
BOX INC
Existing Class A Common Stock |
325.560 | ||||||||
2015-01-05 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
A - Award | 62.500 | 90.854 | 220,43 | ||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2014-12-29 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy) |
P - Purchase | 19.868.965 | 19.868.965 | |||||
2014-12-29 |
|
4 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock |
P - Purchase | 19.868.965 | 35.298.087 | 128,78 | 0,10 | 1.992.857 | 3.540.398 | |
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | 241 | 241 | |||||
2014-12-29 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2014-12-16 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
J - Other | -1.000.000 | 5.619.734 | -15,11 | ||||
2014-12-10 |
|
4 | TRVN |
TREVENA INC
Common Stock |
P - Purchase | 1.000.000 | 4.811.691 | 26,24 | 4,00 | 4.000.000 | 19.246.764 | |
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 504 | 1.009 | 99,80 | ||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2014-11-28 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -1.000.000 | 3.994.106 | -20,02 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Series C Preferred Stock |
C - Conversion | -382.840 | 0 | -100,00 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Series B Preferred Stock |
C - Conversion | -655.321 | 0 | -100,00 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Series A Preferred Stock |
C - Conversion | -2.378.408 | 0 | -100,00 | ||||
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Common Stock |
P - Purchase | 69.112 | 3.502.922 | 2,01 | 16,00 | 1.105.792 | 56.046.752 | |
2014-10-08 |
|
4 | DERM |
Dermira, Inc.
Common Stock |
C - Conversion | 3.416.569 | 3.433.810 | 19.816,54 | ||||
2014-10-02 | 3 | DERM |
Dermira, Inc.
Common Stock |
34.482 | ||||||||
2014-10-02 | 3 | DERM |
Dermira, Inc.
Common Stock |
34.482 | ||||||||
2014-08-29 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -11.600 | 4.659.333 | -0,25 | 7,51 | -87.070 | 34.972.953 | |
2014-08-29 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -146.800 | 4.670.933 | -3,05 | 7,87 | -1.154.846 | 36.745.296 | |
2014-08-29 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -108.300 | 4.817.733 | -2,20 | 8,17 | -884.811 | 39.360.879 | |
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 651 | 651 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | -12.900 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | 12.900 | 12.900 | |||||
2014-08-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
J - Other | -1.290.000 | 4.743.240 | -21,38 | ||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 505 | 505 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2014-08-18 |
|
4 | CVT |
CVENT INC
Common Stock |
J - Other | -1.000.000 | 4.994.106 | -16,68 | ||||
2014-08-12 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -35.540 | 4.926.033 | -0,72 | 6,76 | -240.190 | 33.291.609 | |
2014-08-12 |
|
4 | SNSS |
SUNESIS PHARMACEUTICALS INC
Common Stock |
S - Sale | -675.000 | 4.961.573 | -11,98 | 6,62 | -4.468.568 | 32.846.109 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.558.651 | 0 | -100,00 | ||||
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 230.769 | 1.789.420 | 14,81 | 13,00 | 2.999.997 | 23.262.460 | |
2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
C - Conversion | 1.558.651 | 1.558.651 | |||||
2014-08-05 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
A - Award | 2.680 | 9.105 | 41,71 | 25,00 | 67.000 | 227.625 | |
2014-08-05 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
A - Award | 6.000 | 6.425 | 1.411,76 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series E Preferred Stock |
C - Conversion | -5.987.892 | 0 | -100,00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series D Preferred Stock |
C - Conversion | -8.555.784 | 0 | -100,00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series C Preferred Stock |
C - Conversion | -4.030.224 | 0 | -100,00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Series B Preferred Stock |
C - Conversion | -12.360.000 | 0 | -100,00 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
P - Purchase | 383.333 | 3.216.810 | 13,53 | 12,00 | 4.599.996 | 38.601.720 | |
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 542.381 | 2.833.477 | 23,67 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 801.741 | 2.291.096 | 53,83 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 365.056 | 1.489.355 | 32,47 | ||||
2014-07-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock |
C - Conversion | 1.119.565 | 1.124.299 | 23.649,45 | ||||
2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock |
9.468 | ||||||||
2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock |
9.468 | ||||||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
C - Conversion | -72.190 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
J - Other | -468 | 72.190 | -0,64 | 14,00 | -6.552 | 1.010.660 | |
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
X - Other | 72.658 | 72.658 | |||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock Purchase Warrant |
X - Other | -72.658 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
C - Conversion | -216.573 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
J - Other | -1.402 | 216.573 | -0,64 | 14,00 | -19.628 | 3.032.022 | |
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
X - Other | 217.975 | 217.975 | |||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock Purchase Warrant |
X - Other | -217.975 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series B Preferred Stock |
C - Conversion | -4.404.887 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Series A Preferred Stock |
C - Conversion | -1.415.642 | 0 | -100,00 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
P - Purchase | 510.442 | 6.619.734 | 8,36 | 14,00 | 7.146.188 | 92.676.276 | |
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 72.190 | 6.109.292 | 1,20 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 216.573 | 6.037.102 | 3,72 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 4.404.887 | 5.820.529 | 311,16 | ||||
2014-06-26 |
|
4 | ARDX |
ARDELYX, INC.
Common Stock |
C - Conversion | 1.415.642 | 1.415.642 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 120 | 120 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | -5.000 | 0 | -100,00 | ||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | 5.000 | 5.000 | |||||
2014-06-06 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | -500.000 | 2.384.221 | -17,34 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Common Stock (right to buy) |
C - Conversion | 55.831 | 55.831 | |||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Series D Preferred Stock (right to buy) |
C - Conversion | -55.831 | 0 | -100,00 | 15,81 | -882.470 | ||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Preferred Stock |
C - Conversion | -411.234 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series D Preferred Stock |
C - Conversion | -1.236.487 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series C Preferred Stock |
C - Conversion | -531.758 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series B Preferred Stock |
C - Conversion | -383.249 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series A Preferred Stock |
C - Conversion | -797.208 | 0 | -100,00 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 411.234 | 3.943.269 | 11,64 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 1.236.487 | 3.532.035 | 53,86 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 531.758 | 2.295.548 | 30,15 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 383.249 | 1.763.790 | 27,76 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 797.208 | 1.380.541 | 136,66 | ||||
2014-04-24 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
P - Purchase | 583.333 | 583.333 | 12,00 | 6.999.996 | 6.999.996 | ||
2014-04-09 |
|
4 | OPWR |
OPOWER, INC.
Series C Preferred Stock |
C - Conversion | -1.123.596 | 0 | -100,00 | ||||
2014-04-09 |
|
4 | OPWR |
OPOWER, INC.
Series B Preferred Stock |
C - Conversion | -7.866.170 | 0 | -100,00 | ||||
2014-04-09 |
|
4 | OPWR |
OPOWER, INC.
Common Stock |
C - Conversion | 8.989.766 | 8.989.766 | |||||
2014-04-03 |
|
4 | HIVE |
AEROHIVE NETWORKS, INC
Series E Preferred Stock |
C - Conversion | -1.065.143 | 0 | -100,00 | ||||
2014-04-03 |
|
4 | HIVE |
AEROHIVE NETWORKS, INC
Series D Preferred Stock |
C - Conversion | -3.588.446 | 0 | -100,00 | ||||
2014-04-03 |
|
4 | HIVE |
AEROHIVE NETWORKS, INC
Common Stock |
C - Conversion | 4.653.589 | 4.673.589 | 23.267,94 | ||||
2014-03-27 | 3 | HIVE |
AEROHIVE NETWORKS, INC
Common Stock |
40.000 | ||||||||
2014-03-27 | 3 | HIVE |
AEROHIVE NETWORKS, INC
Common Stock |
40.000 | ||||||||
2014-03-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | 145 | 425 | 51,79 | ||||
2014-03-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | -6.000 | 0 | -100,00 | ||||
2014-03-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | 6.000 | 6.000 | |||||
2014-03-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | -600.000 | 556.692 | -51,87 | ||||
2014-02-21 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | 140 | 280 | 100,00 | ||||
2014-02-21 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | -5.800 | 0 | -100,00 | ||||
2014-02-21 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | 5.800 | 5.800 | |||||
2014-02-21 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | -580.000 | 1.156.692 | -33,40 | ||||
2014-02-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | 140 | 140 | |||||
2014-02-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | -5.800 | 0 | -100,00 | ||||
2014-02-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | 5.800 | 5.800 | |||||
2014-02-11 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
J - Other | -580.000 | 1.736.692 | -25,04 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series C Preferred Stock |
C - Conversion | -4.840.686 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
C - Conversion | -1.462.857 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
S - Sale | -487.143 | 1.462.857 | -24,98 | 1,13 | -549.984 | 1.651.566 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Preferred Stock |
X - Other | 550.000 | 1.950.000 | 39,29 | 1,00 | 550.000 | 1.950.000 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B-1 Warrants |
X - Other | -550.000 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series B Preferred Stock |
C - Conversion | -8.400.000 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Series A Preferred Stock |
C - Conversion | -6.000.000 | 0 | -100,00 | ||||
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
P - Purchase | 472.410 | 3.811.691 | 14,15 | 7,00 | 3.306.870 | 26.681.837 | |
2014-02-07 |
|
4 | TRVN |
TREVENA INC
Common Stock |
C - Conversion | 3.339.281 | 3.339.281 | |||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Series E Convertible Preferred Stock |
C - Conversion | -612.089 | 0 | -100,00 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Series D Convertible Preferred Stock |
C - Conversion | -401.837 | 0 | -100,00 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Series C Convertible Preferred Stock |
C - Conversion | -2.242.087 | 0 | -100,00 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Common Stock |
C - Conversion | 612.089 | 3.256.013 | 23,15 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Common Stock |
C - Conversion | 401.837 | 2.643.924 | 17,92 | ||||
2014-01-29 |
|
4 | CRCM |
Care.com Inc
Common Stock |
C - Conversion | 2.242.087 | 2.242.087 | |||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock Warrant (right to buy) |
X - Other | -56.983 | 0 | -100,00 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock Warrant (right to buy) |
X - Other | -160.672 | 0 | -100,00 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock Warrant (right to buy) |
X - Other | -749.721 | 0 | -100,00 | ||||
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
D - Sale to Issuer | -13.551 | 2.316.692 | -0,58 | 10,96 | -148.519 | 25.390.944 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
X - Other | 56.983 | 2.330.243 | 2,51 | 10,96 | 624.534 | 25.539.463 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
D - Sale to Issuer | -38.210 | 2.273.260 | -1,65 | 10,96 | -418.782 | 24.914.930 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
X - Other | 160.672 | 2.311.470 | 7,47 | 10,96 | 1.760.965 | 25.333.711 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
D - Sale to Issuer | -260.280 | 2.150.798 | -10,80 | 16,00 | -4.164.480 | 34.412.768 | |
2014-01-28 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
X - Other | 749.721 | 2.411.078 | 45,13 | 16,00 | 11.995.536 | 38.577.248 | |
2014-01-23 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -169.887 | 5.994.106 | -2,76 | 35,50 | -6.030.988 | 212.790.763 | |
2014-01-21 |
|
4 | CVT |
CVENT INC
Common Stock |
S - Sale | -1.132.589 | 6.163.993 | -15,52 | 35,50 | -40.206.910 | 218.821.752 | |
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Series A-1 Preferred Stock |
C - Conversion | -11.824.058 | 0 | -100,00 | ||||
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
P - Purchase | 512.500 | 4.093.377 | 14,31 | 8,00 | 4.100.000 | 32.747.016 | |
2014-01-15 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock |
C - Conversion | 3.580.877 | 3.580.877 | |||||
2014-01-03 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
A - Award | 13.755 | 28.354 | 94,22 | ||||
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 25.800 | 406.500 | 6,78 | 19,31 | 498.185 | 7.849.312 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 23.700 | 380.700 | 6,64 | 20,31 | 481.269 | 7.730.761 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 163.620 | 357.000 | 84,61 | 19,04 | 3.115.538 | 6.797.744 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 152.459 | 193.380 | 372,57 | 19,99 | 3.047.335 | 3.865.260 | |
2013-11-18 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 40.921 | 40.921 | 20,91 | 855.654 | 855.654 | ||
2013-11-13 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -201.012 | 1.661.357 | -10,79 | 32,37 | -6.506.758 | 53.778.126 | |
2013-11-13 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
S - Sale | -903.229 | 1.862.369 | -32,66 | 32,37 | -29.237.523 | 60.284.885 | |
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 4.815 | 7.944 | 153,88 | ||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -200.000 | 0 | -100,00 | ||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 200.000 | 200.000 | |||||
2013-09-17 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -20.000.000 | 54.184.956 | -26,96 | ||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 3.129 | 3.129 | |||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -130.000 | 0 | -100,00 | ||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | 130.000 | 130.000 | |||||
2013-08-16 |
|
4 | GRPN |
Groupon, Inc.
Class A Common Stock |
J - Other | -13.000.000 | 74.184.956 | -14,91 | ||||
2013-08-14 |
|
4 | CVT |
CVENT INC
Series A Preferred Stock |
C - Conversion | -7.296.582 | 0 | -100,00 | ||||
2013-08-14 |
|
4 | CVT |
CVENT INC
Common Stock |
C - Conversion | 7.296.582 | 7.296.582 | |||||
2013-07-18 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
D - Sale to Issuer | -5.833.213 | 0 | -100,00 | ||||
2013-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Series B Preferred Stock |
C - Conversion | -16.899.721 | 0 | -100,00 | ||||
2013-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
P - Purchase | 400.000 | 6.033.240 | 7,10 | 15,00 | 6.000.000 | 90.498.600 | |
2013-06-07 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
C - Conversion | 5.633.240 | 5.633.240 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 829 | 829 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -16.450 | 0 | -100,00 | ||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | 16.450 | 16.450 | |||||
2013-06-05 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
J - Other | -1.645.000 | 9.854.255 | -14,31 | ||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 575 | 575 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -11.399 | 0 | -100,00 | ||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 11.399 | 11.399 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -1.139.890 | 2.279.781 | -33,33 | ||||
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Series C Preferred Stock |
C - Conversion | -44.249.588 | 0 | -100,00 | ||||
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Series C Preferred Stock |
S - Sale | -95.980 | 44.249.588 | -0,22 | 0,88 | -83.982 | 38.718.390 | |
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Series C Preferred Stock |
X - Other | 122.602 | 44.345.568 | 0,28 | 0,68 | 83.982 | 30.376.714 | |
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Warrant to Purchase Series C Preferred Stock (right to buy) |
X - Other | -122.602 | 0 | -100,00 | ||||
2013-05-29 |
|
4 | ECOM |
CHANNELADVISOR CORP
Common Stock |
C - Conversion | 2.765.599 | 2.765.599 | |||||
2013-05-23 | 3 | ILIU |
INTERLEUKIN GENETICS INC
Common Stock |
15.429.122 | ||||||||
2013-04-30 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
A - Award | 14.599 | 14.599 | |||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -6.165.747 | 0 | -100,00 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Secured Convertible Promissory Note |
C - Conversion | -633.219 | 0 | -100,00 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Warrant (right to buy) |
C - Conversion | -156.250 | 0 | -100,00 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 625.000 | 5.833.213 | 12,00 | 8,00 | 5.000.000 | 46.665.704 | |
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 4.418.940 | 5.208.213 | 559,87 | ||||
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 633.219 | 789.273 | 405,77 | 8,00 | 5.065.752 | 6.314.184 | |
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
S - Sale | -196 | 156.054 | -0,13 | 8,00 | -1.568 | 1.248.432 | |
2013-04-17 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 156.250 | 156.250 | 0,01 | 1.562 | 1.562 | ||
2013-04-11 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Secured Convertible Promissory Note |
A - Award | 633.219 | 633.219 | |||||
2013-04-11 |
|
4 | OMTH |
Omthera Pharmaceuticals, Inc.
Warrant (right to buy) |
A - Award | 156.250 | 156.250 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | -2.321.212 | 4.642.425 | -33,33 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 559 | 1.730 | 47,74 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -23.212 | 0 | -100,00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -23.212 | 0 | -100,00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -2.321.212 | 0 | -100,00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
C - Conversion | 2.321.212 | 2.321.212 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | -2.321.212 | 4.642.425 | -33,33 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 1.171 | 1.171 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -23.212 | 0 | -100,00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | 23.212 | 23.212 | |||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
J - Other | -2.321.212 | 0 | -100,00 | ||||
2013-04-11 |
|
4 | WDAY |
Workday, Inc.
Class A Common Stock |
C - Conversion | 2.321.212 | 2.321.212 | |||||
2012-10-30 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
S - Sale | -1.597.787 | 8.196.614 | -16,31 | 13,44 | -21.478.252 | 110.182.984 | |
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | 6.963.636 | 13.927.273 | 100,00 | ||||
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -6.963.636 | 0 | -100,00 | ||||
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Class B Common Stock |
C - Conversion | 6.963.637 | 6.963.637 | |||||
2012-10-18 |
|
4 | WDAY |
Workday, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -6.963.637 | 0 | -100,00 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -64.634 | 0 | -100,00 | 27,67 | -1.788.494 | ||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 1.084 | 3.751 | 40,64 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -45.000 | 0 | -100,00 | ||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 45.000 | 45.000 | |||||
2012-09-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -4.500.000 | 9.038.379 | -33,24 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-1 Preferred Stock |
C - Conversion | -611.185 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
C - Conversion | -2.043 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
C - Conversion | -2.043 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
J - Other | -51.744 | 2.043 | -96,20 | 10,00 | -517.440 | 20.430 | |
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
J - Other | -51.744 | 2.043 | -96,20 | 10,00 | -517.440 | 20.430 | |
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
X - Other | 53.787 | 53.787 | |||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
X - Other | 53.787 | 53.787 | |||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Preferred Stock Warrant (right to buy) |
X - Other | -53.787 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Preferred Stock Warrant (right to buy) |
X - Other | -53.787 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock Warrant (right to buy) |
X - Other | -125.291 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Series C-2 Preferred Stock |
C - Conversion | -898.808 | 0 | -100,00 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
P - Purchase | 500.000 | 2.884.221 | 20,97 | 10,00 | 5.000.000 | 28.842.210 | |
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 177.841 | 2.384.221 | 8,06 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 180.459 | 2.206.740 | 8,91 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 434.096 | 2.026.281 | 27,26 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 2.043 | 1.592.185 | 0,13 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 2.043 | 1.592.185 | 0,13 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
J - Other | -51.119 | 1.588.099 | -3,12 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
X - Other | 125.291 | 1.639.218 | 8,28 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 898.808 | 1.513.927 | 146,12 | ||||
2012-08-02 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
C - Conversion | 611.185 | 615.119 | 15.535,97 | ||||
2012-07-25 | 3 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
3.934 | ||||||||
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Series B Preferred Stock |
C - Conversion | -5.253.859 | 0 | -100,00 | ||||
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Series A Preferred Stock |
C - Conversion | -5.134.285 | 0 | -100,00 | ||||
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
P - Purchase | 1.111.111 | 11.499.255 | 10,70 | 13,50 | 14.999.998 | 155.239.942 | |
2012-07-03 |
|
4 | TSRO |
TESARO, Inc.
Common Stock |
C - Conversion | 10.388.144 | 10.388.144 | |||||
2012-05-01 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 1.688 | 2.667 | 172,42 | ||||
2012-05-01 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -69.998 | 0 | -100,00 | ||||
2012-04-04 |
|
4 | MM |
Millennial Media Inc.
Series D Preferred Stock |
C - Conversion | -1.758.302 | 0 | -100,00 | ||||
2012-04-04 |
|
4 | MM |
Millennial Media Inc.
Series C Preferred Stock |
C - Conversion | -8.036.099 | 0 | -100,00 | ||||
2012-04-04 |
|
4 | MM |
Millennial Media Inc.
Common Stock |
C - Conversion | 9.794.401 | 9.794.401 | |||||
2012-03-16 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 69.998 | 16,67 | ||||
2012-03-16 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 13.538.379 | -6,88 | ||||
2012-03-13 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 9.998 | 59.998 | 20,00 | ||||
2012-03-13 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 14.538.379 | -6,44 | ||||
2012-03-07 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 50.000 | 25,00 | ||||
2012-03-07 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 15.538.379 | -6,05 | ||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 97 | 97 | |||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | -4.000 | 0 | -100,00 | ||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | 4.000 | 4.000 | |||||
2012-03-01 |
|
4 | ECHO |
Echo Global Logistics, Inc.
Common Stock |
J - Other | -400.000 | 2.020.219 | -16,53 | ||||
2012-02-29 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 40.000 | 33,33 | ||||
2012-02-29 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 16.538.379 | -5,70 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 30.000 | 50,00 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 17.538.379 | -5,39 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 20.000 | 100,00 | ||||
2012-02-27 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 18.538.379 | -5,12 | ||||
2012-02-23 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2012-02-23 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 19.538.379 | -4,87 | ||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 244 | 979 | 33,20 | ||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2012-02-14 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 20.538.379 | -4,64 | ||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 244 | 735 | 49,69 | ||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -10.000 | 0 | -100,00 | ||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 10.000 | |||||
2012-02-09 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 21.538.379 | -4,44 | ||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
S - Sale | -23.083 | 64.634 | -26,32 | 23,05 | -532.063 | 1.489.814 | |
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 491 | 491 | |||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -20.000 | 0 | -100,00 | ||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | 10.000 | 20.000 | 100,00 | ||||
2012-02-06 |
|
4 | FIO |
FUSION-IO, INC.
Common Stock |
J - Other | -1.000.000 | 22.538.379 | -4,25 |